Pliant Therapeutics Inc. has released a corporate presentation detailing progress in its integrin-based therapeutics pipeline. The lead program, PLN-101095, is an oral small molecule inhibitor targeting αvβ8 and αvβ1 integrins for the treatment of immune checkpoint inhibitor (ICI)-resistant solid tumors. In the Phase 1 study, four clinical responders—including one complete response and three partial responses—were observed among heavily pre-treated patients at the highest dose levels, with a median treatment duration of 15 months for responders. The compound demonstrated dose-dependent plasma exposure and was well tolerated. Pliant is advancing a Phase 1b dose expansion to further assess efficacy in non-small cell lung cancer and other tumor types. Additionally, the company is developing a cell-specific drug delivery platform for siRNA payloads, with broad applicability across multiple disease areas. Pliant reports a strong cash position to fund operations through 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief on January 27, 2026, and is solely responsible for the information contained therein.